936563-96-1 Ibrutinib (PCI-32765) AKSci X7513
 
 
Loading Please Wait...
  X7513    
Ibrutinib (PCI-32765), 99% (HPLC)
 
(R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
IDENTITY
CAS Number:936563-96-1
MDL Number:MFCD20261150
MF:C25H24N6O2
MW:440.5
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99% (HPLC)
Physical Form (at 20°C):Solid
Density:1.3
Refractive Index:1.69
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO
Application(s):Btk
Form:Free base
Research Area:Leukemia

REVIEW
 Ibrutinib is an experimental anticancer drug recently approved for mantle cell lymphoma. It is a selective and covalent inhibitor of the enzyme Bruton''s tyrosine kinase (BTK). Ibrutinib is currently under development for other B-cell malignancies including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. It was originally synthesized as one of a series of small molecules that inactivate BTK through covalent binding to cysteine-481 near the ATP binding domain of BTK, by means of a Michael acceptor for binding to the target cysteine.

REFERENCES
[1]Honigberg, Lee; Verner, Erik; Pan, Zhengying Preparation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as bruton''s tyrosine kinase inhibitors U.S. Pat. Appl. Publ. (2008), US 20080076921 A1 20080327.
[2] Honigberg, Lee; Verner, Erik; Pan, Zhengying Preparation of substituted pyrazolopyrimidinamines as inhibitors of Bruton''s tyrosine kinase U.S. Pat. Appl. Publ. (2008), US 20080108636 A1 20080508.
[3] Honigberg, Lee; Verner, Erik; Buggy, Joseph J.; Loury, David; Chen, Wei Preparation of substituted pyrazolopyrimidinamines as therapeutic inhibitors of Bruton''s tyrosine kinase and other kinases PCT Int. Appl. (2008), WO 2008121742 A2 20081009.
[4] Pan, Z; Scheerens, H; Li, SJ; Schultz, BE; Sprengeler, PA; Burrill, LC; Mendonca, RV; Sweeney, MD; Scott, KC; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.Discovery of selective irreversible inhibitors for Bruton''s tyrosine kinase. ChemMedChem 2007, 2 (1): 58-61.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of April 19, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > Chemotherapeutics


PubChem